Cormorant Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Cormorant Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,175,000	Closed	-$25.4M	–	62
2023 Q4	$25.4M	Buy	+1,175,000	New	+$18.1M	1.21%	24
2017 Q2	–	Sell	-240,403	Closed	-$3.3M	–	77
2017 Q1	$3.3M	Hold	240,403	–	–	0.48%	48
2016 Q4	$1.72M	Hold	240,403	–	–	0.23%	65
2016 Q3	$3.65M	Buy	240,403 +25,984	+12%	+$342K	0.4%	59
2016 Q2	$2.11M	Hold	214,419	–	–	0.3%	58
2016 Q1	$2.86M	Buy	+214,419	New	+$2.7M	0.43%	54

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cormorant Asset Management's SNDX Position: Q1 2024 in Review

Cormorant Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2024, closing a stake of 1,175,000 shares — an estimated $25.4M sold.

Cormorant Asset Management first reported a position in SNDX in Q1 2016 and held it in 6 quarters. The position peaked at $25.4M in Q4 2023. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

Cormorant Asset Management reported no remaining Syndax Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cormorant Asset Management sold 1,175,000 Syndax Pharmaceuticals shares in Q1 2024, an estimated $25.4M.
Cormorant Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Cormorant Asset Management's Syndax Pharmaceuticals position peaked at $25.4M in Q4 2023.
189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.